---
figid: PMC10385692__pharmaceutics-15-01936-g001
pmcid: PMC10385692
image_filename: PMC10385692__pharmaceutics-15-01936-g001.jpg
figure_link: /pmc/articles/PMC10385692/figure/F1/
number: Figure 1
figure_title: Application of substrate reduction therapy (SRT) and enzyme replacement
  therapy (ERT) on the metabolic pathway of glycosphingolipids.
caption: 'Application of substrate reduction therapy (SRT) and enzyme replacement
  therapy (ERT) on the metabolic pathway of glycosphingolipids. GCS: Glucosylceramide
  synthase. α-Gal A: α-Galactosidase A. Gb3S: Gb3 Synthase. FD: Fabry disease. Gb3:
  Globotriaosylceramide. Gb4: Globotetraosylceramide'
article_title: Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic
  Acid for Substrate Reduction Therapy in Fabry Disease
citation: Marina Beraza-Millor, et al. Pharmaceutics. 2023 Jul;15(7).
year: '2023'
pub_date: 2023-7-
epub_date: 2023-7-12
doi: 10.3390/pharmaceutics15071936
journal_title: Pharmaceutics
journa_nlm_ta: Pharmaceutics
publisher_name: MDPI
keywords:
- substrate reduction therapy
- solid lipid nanoparticles
- siRNA
- Fabry disease
- Gb3 synthase
- gold nanoparticles
---
